Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.
Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Kalbakis K, Millaki G, Mavroudis D, Georgoulias V. Souglakos J, et al. Among authors: pallis a. Breast Cancer Res. 2006;8(4):R36. doi: 10.1186/bcr1516. Breast Cancer Res. 2006. PMID: 16846533 Free PMC article.
Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.
Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N, Kalmanti L, Kalbakis K, Agelaki S, Kalykaki A, Stournaras C, Stathopoulos E, Georgoulias V, Mavroudis D. Apostolaki S, et al. Among authors: pallis a. Breast Cancer Res Treat. 2009 Oct;117(3):525-34. doi: 10.1007/s10549-008-0239-3. Epub 2008 Nov 19. Breast Cancer Res Treat. 2009. PMID: 19016323
Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.
Apostolaki S, Perraki M, Pallis A, Bozionelou V, Agelaki S, Kanellou P, Kotsakis A, Politaki E, Kalbakis K, Kalykaki A, Vamvakas L, Georgoulias V, Mavroudis D. Apostolaki S, et al. Among authors: pallis a. Ann Oncol. 2007 May;18(5):851-8. doi: 10.1093/annonc/mdl502. Epub 2007 Feb 14. Ann Oncol. 2007. PMID: 17301075 Free article.
Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer.
Xenidis N, Markos V, Apostolaki S, Perraki M, Pallis A, Sfakiotaki G, Papadatos-Pastos D, Kalmanti L, Kafousi M, Stathopoulos E, Kakolyris S, Mavroudis D, Georgoulias V. Xenidis N, et al. Among authors: pallis a. Ann Oncol. 2007 Oct;18(10):1623-31. doi: 10.1093/annonc/mdm208. Epub 2007 May 21. Ann Oncol. 2007. PMID: 17515404 Free article.
ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.
Pallis AG, Mavroudis D, Androulakis N, Souglakos J, Kouroussis C, Bozionelou V, Vlachonikolis IG, Georgoulias V. Pallis AG, et al. Lung Cancer. 2003 Jun;40(3):301-7. doi: 10.1016/s0169-5002(03)00079-5. Lung Cancer. 2003. PMID: 12781429 Clinical Trial.
Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial.
Pallis AG, Christofillakis Ch, Tselepatiotis E, Agelaki S, Vamvakas L, Souglakos J, Vardakis N, Kalykaki A, Kotsakis A, Argiraki A, Mavroudis D, Georgoulias V. Pallis AG, et al. Lung Cancer. 2007 Jan;55(1):101-7. doi: 10.1016/j.lungcan.2006.08.019. Epub 2006 Oct 17. Lung Cancer. 2007. PMID: 17049673 Clinical Trial.
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.
Pallis AG, Voutsina A, Kalikaki A, Souglakos J, Briasoulis E, Murray S, Koutsopoulos A, Tripaki M, Stathopoulos E, Mavroudis D, Georgoulias V. Pallis AG, et al. Br J Cancer. 2007 Dec 3;97(11):1560-6. doi: 10.1038/sj.bjc.6604068. Epub 2007 Nov 13. Br J Cancer. 2007. PMID: 18000506 Free PMC article.
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.
Pallis AG, Agelaki S, Kakolyris S, Kotsakis A, Kalykaki A, Vardakis N, Papakotoulas P, Agelidou A, Geroyianni A, Agelidou M, Hatzidaki D, Mavroudis D, Georgoulias V; Hellenic Oncology Research Group (HORG). Pallis AG, et al. Lung Cancer. 2008 Dec;62(3):356-63. doi: 10.1016/j.lungcan.2008.03.030. Epub 2008 May 22. Lung Cancer. 2008. PMID: 18501466
81 results